References
- DoghramjiPPWortmannRLHyperuricemia and gout: new concepts in diagnosis and managementPostgrad Med201212469810923322143
- BossGRSeegmillerJEHyperuricemia and gout. Classification, complications and managementN Engl J Med19793002614591468221806
- NeogiTClinical practice. GoutN Engl J Med2011364544345221288096
- KhannaDFitzgeraldJDKhannaPPAmerican College of Rheumatology2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care Res (Hoboken)201264101431144623024028
- RichettePPerez-RuizFDohertyMImproving cardiovascular and renal outcomes in gout: what should we target?Nat Rev Rheumatol2014101165466125136785
- ZhangWDohertyMBardinTEULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Ann Rheum Dis200665101312132416707532
- US Food and Drug Administration, HHSInternational Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugsFed Regist200570202611346113516237860
- BobulescuIAMoeOWRenal transport of uric acid: evolving concepts and uncertaintiesAdv Chronic Kidney Dis201219635837123089270
- FleischmannRKerrBYehLTPharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemiaRheumatology (Oxford)201453122167217424509406
- GirardetJ-LMinerJNUrate crystal deposition disease and gout – new therapies for an old problemAnnu Rep Med Chem201449151164
- GarnettCEBeasleyNBhattaramVAConcentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory reviewJ Clin Pharmacol2008481131818094216
- BloomfieldDMKostJTGhoshKThe effect of moxifloxacin on QTc and implications for the design of thorough QT studiesClin Pharmacol Ther200884447548019238652
- ShahRRMaison-BlanchePDuvauchelleTRobertPDenisEEstablishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT studyEur J Clin Pharmacol201571121451145926423621
- The International Council for Harmonisation [webpage on the Internet]International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human UseThe Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E-14The International Council for Harmonisation Available from: http://www.ich.org/products/guidelines/efficacy/article/efficacyguidelinesAccessed April 4, 2016